| A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL (NCT05365100) | BioNova Pharmaceuticals (Shanghai) LTD. | 2022-07-01 |
| HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL (NCT05176691) | Hutchmed | 2022-02-15 |
| First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML (NCT04840784) | Shengke Pharmaceuticals Pty Ltd | 2021-06-29 |
| A Study of IGN002 for Refractory NHL (NCT02847949) | Spectrum Pharmaceuticals, Inc | 2021-01-01 |
| Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma. (NCT04639739) | Xinqiao Hospital of Chongqing | 2020-12-17 |
| FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL (NCT04555811) | Masonic Cancer Center, University of Minnesota | 2020-09-22 |
| Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients (NCT04440436) | Beijing Immunochina Medical Science & Technology Co., Ltd. | 2020-06-04 |
| A National Study for Blood Based Response Monitoring of B-cell Lymphoma Patients (NCT04139252) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2020-03-17 |
| Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma (NCT03789240) | National Cancer Institute (NCI) | 2019-08-22 |
| Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma (NCT04002947) | National Cancer Institute (NCI) | 2019-08-05 |
| A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant (NCT03739502) | University of Rochester | 2019-02-28 |
| The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL (NCT03463057) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2018-08-30 |
| Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies (NCT03465540) | Amgen | 2018-08-17 |
| Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) (NCT03527147) | Acerta Pharma BV | 2018-06-19 |
| Safety and Efficacy Evaluation of Decitabine With R-GDP (NCT03535753) | Beijing Immunochina Medical Science & Technology Co., Ltd. | 2017-09-01 |
| PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) (NCT02702492) | Karyopharm Therapeutics Inc | 2016-06-08 |
| Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies (NCT02315612) | National Cancer Institute (NCI) | 2014-12-12 |
| Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma (NCT02110563) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2014-04-01 |
| Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL (NCT01101581) | Gilead Sciences | 2010-05-01 |
| Umbilical Cord Blood Transplant for Hematological Malignancies (NCT00891592) | University of Pennsylvania | 2009-01-01 |
| Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL (NCT00546793) | Gilead Sciences | 2008-01-01 |
| Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease (NCT00515892) | Cambridge Antibody Technology | 2007-08-01 |
| Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft (NCT00814983) | Duke University | 2007-07-01 |
| Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877 (NCT00471367) | AstraZeneca | 2007-04-01 |
| CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation (NCT00333190) | Dana-Farber Cancer Institute | 2005-09-01 |
| Safety Study of NHL With 90Y-hLL2 IgG (NCT00421395) | Gilead Sciences | 2002-08-01 |
| Influence of Corn Farming on the Immune System (NCT00342121) | National Cancer Institute (NCI) | 2002-05-03 |
| Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia (NCT00513175) | University of California, San Francisco | 2001-10-01 |
| Allogeneic Transplantation From Related Haploidentical Donors (NCT00185692) | Stanford University | 2000-08-01 |